Prostate cancer is the fifth leading cause of cancer death in men. When it is caught early and localised, the five-year survival rate is close to 100%. But when it progresses to metastatic disease — when it spreads beyond the prostate — that survival rate drops to 30%. And when it becomes castration-resistant, developing the ability to grow independently of the androgens that standard therapy targets, it is currently considered incurable.

This is the clinical reality that a team of researchers at University College Dublin set out to engage with when they published a study in the Journal of Natural Products in 2023, asking a focused question: what does cannabidiol do to prostate cancer cells, how exactly does it do it, and does the effect extend to the cancer's ability to invade surrounding tissue?

The answers they found are detailed, mechanistically grounded, and connect directly to what we have been building in this series — particularly to last week's ovarian cancer study, which identified the PI3K/AKT/mTOR signalling axis as a key target of cannabinoid action. That same signalling axis appears here, through a different molecular entry point, in a different cancer, reinforcing a pattern that the broader research literature is increasingly difficult to dismiss.

The Problem With Prostate Cancer Treatment

Understanding what this study found requires understanding what makes prostate cancer so difficult to treat once it escapes early-stage management. Most prostate cancers are initially driven by androgens — the male hormones, primarily testosterone. Androgen deprivation therapy removes that fuel source and works well initially. The problem is that over time, tumour cells adapt. They develop the ability to maintain androgen receptor signalling without the androgens themselves, or they find entirely androgen-independent growth pathways. At that point, the standard treatment no longer controls the disease.

The two key features of advanced prostate cancer that any new therapeutic approach needs to address are proliferation — the uncontrolled division of cancer cells that drives tumour growth — and invasion — the ability of cancer cells to break out of the prostate, penetrate surrounding tissue, and establish new tumour foci elsewhere in the body. Metastasis is the cause of approximately 90% of all cancer deaths. Any compound that can meaningfully inhibit both of these behaviours in prostate cancer cells is scientifically worth taking seriously.

How the Study Was Designed

The researchers used three established prostate cancer cell lines that represent different stages and hormone sensitivities of the disease. DU145 and PC-3 are both androgen-insensitive — they do not depend on androgens to grow, making them models of advanced, treatment-resistant prostate cancer. LNCaP is androgen-sensitive, modelling earlier-stage hormone-driven disease.

CBD was supplied by GreenLight Pharmaceuticals at a purity above 99.7%, verified by convergence chromatography. This level of purity matters for mechanistic research — it ensures that any effect observed is attributable to CBD specifically, not to other constituents in a cannabis extract.

The study also included two noncancerous prostate epithelial cell lines — PWR-1E and RWPE-1 — to determine whether CBD's effects are specific to cancer cells or whether they also affect healthy tissue. This is the same design principle we highlighted last week in the ovarian cancer study, and it is the correct way to assess therapeutic potential versus non-selective toxicity.

What CBD Did to Cancer Cell Viability

Under serum deprivation conditions — which remove the buffering effect of proteins in growth media — CBD reduced the viability of all three cancer cell lines in a dose-dependent manner. The IC50 values at 72 hours were 1.5 micromolar for DU145, 2.9 micromolar for PC-3, and 2.6 micromolar for LNCaP cells.

The study also tested CBD in the presence of serum, which reflects more realistic growth conditions and is known to reduce cannabinoid efficacy because serum proteins bind to CBD and reduce its free concentration in the medium. Under serum conditions, the IC50 values rose to 12.3 micromolar for DU145, 10.5 micromolar for PC-3, and 18.0 micromolar for LNCaP. The androgen-independent lines — DU145 and PC-3 — remained more sensitive to CBD than the androgen-dependent LNCaP line under these conditions, which is a relevant finding given that androgen-independent disease represents the harder therapeutic challenge.

Beyond simple viability, the researchers used multiple complementary methods to understand what was actually happening to the cells. Flow cytometry confirmed that CBD significantly reduced total cell counts in both DU145 and PC-3 lines. A clonogenic assay — which tests a cell's ability to form a colony after treatment, reflecting long-term survival and proliferative potential — showed that CBD pretreatment reduced PC-3 colony formation by approximately 25% after seven days of recovery without further treatment. This means CBD's inhibitory effect persists beyond the treatment period, which is relevant for any therapeutic application.

High-content fluorescence microscopy revealed that at doses of 5 and 10 micromolar — in the presence of serum — CBD significantly reduced cell confluency in DU145 and PC-3 cells, confirming inhibition of proliferation. Crucially, CBD did not significantly increase markers of cell death at these concentrations. The primary effect in cancer cells grown with serum was the slowing of proliferation, not the induction of apoptosis. This is an important distinction: CBD appears to work predominantly as a cytostatic agent in prostate cancer cells under physiologically relevant conditions rather than as an acute cell killer.

The Receptor Mystery — What CBD Is Not Using

One of the most scientifically interesting findings in this study is what CBD is not doing. The conventional understanding of cannabinoid pharmacology centres on the CB1 and CB2 receptors — the two primary cannabinoid receptors that THC binds to directly. Many of CBD's effects in other contexts have been attributed to these receptors, to the TRPV1 ion channel, and to GPR55, a receptor that some researchers consider a third cannabinoid receptor.

To determine which receptors were mediating CBD's effects in prostate cancer cells, the researchers pretreated cells with selective blockers of each of these targets before applying CBD. If blocking a receptor reduced CBD's effect, that receptor would be implicated in the mechanism. None of them were.

This finding does not mean CBD has no receptor targets — it means the targets that mediate its effects in prostate cancer cells remain to be identified. The researchers suggest CBD may be acting through PPARgamma, mitochondrial proteins such as VDAC1, ion channels including TRPM8 and TRPA1, serotonin receptors, or steroid receptors. This is consistent with CBD's known pharmacological promiscuity — it interacts with a wide range of molecular targets across different cell types, and the relevant target appears to vary by tissue and cancer type.

For the purposes of understanding what this means practically: CBD's anticancer effects in prostate cells appear to be receptor-independent, at least with respect to the classical cannabinoid receptor system. This matters because it suggests the mechanism is not simply a consequence of endocannabinoid system modulation but reflects a more fundamental disruption of cancer cell biology.

The Cell Cycle — Where the Action Is

Having established that CBD inhibits prostate cancer cell proliferation, the researchers investigated why — specifically, what happens to the proteins that drive the cell cycle.

The cell cycle is the sequence of events that a cell goes through to duplicate itself and divide. It has multiple checkpoints — the G1/S transition and the G2/M transition are the two most important — and each checkpoint is controlled by a set of proteins called cyclins and cyclin-dependent kinases. Cancer cells typically have dysregulated cell cycle control, which allows them to divide far more rapidly than normal cells. Compounds that restore that control by reducing the levels or activity of these proteins can slow or stop cancer cell proliferation.

Taken together, CBD appears to block cell cycle progression at both major checkpoints simultaneously — the G1/S transition, where the cell commits to DNA replication, and the G2/M transition, where it commits to division. This dual-checkpoint disruption is consistent with the potent anti-proliferative effect observed in the viability and confluency assays, and it adds mechanistic specificity to what the broader literature had previously described in more general terms.

The AKT story adds another dimension. AKT is a protein kinase — a molecular switch — whose phosphorylated, active form promotes cancer cell proliferation, survival, and invasiveness. AKT hyperphosphorylation is a common feature of prostate cancer, observed in approximately 50% of cases. Last week's ovarian cancer study showed that the CBD:THC combination markedly reduced phospho-AKT levels as part of the PI3K/AKT/mTOR cascade. Here, CBD alone significantly reduced AKT phosphorylation by approximately 40% in DU145 cells. This connects prostate cancer to the same signalling axis we documented in ovarian cancer, glioblastoma, and multiple other cancer types across this series — suggesting AKT phosphorylation inhibition may be one of the more consistent targets of CBD's anticancer action.

Stopping the Spread — The Invasion Finding

The anti-invasion data may be the most clinically significant finding in the study, because invasion is the behaviour that ultimately kills patients.

Using a Transwell invasion assay with extracellular matrix — a standard method for measuring how readily cells can push through a barrier that mimics the tissue they would need to penetrate to spread — the researchers found that a noncytotoxic dose of CBD reduced PC-3 cell invasiveness by approximately 30%. This is important phrasing: noncytotoxic means the dose was not high enough to kill cells. The reduction in invasiveness occurred at a concentration at which the cells were still alive and growing — it was a change in cell behaviour, not a consequence of cell death.

The E-cadherin finding deserves emphasis. The loss of E-cadherin is one of the hallmarks of epithelial-mesenchymal transition — the process by which cancer cells acquire the capacity to invade and metastasise. CBD is not merely slowing cell division in PC-3 cells; it appears to be partially reversing the molecular signature of metastatic behaviour. A compound that can promote a noninvasive epithelial phenotype in highly metastatic cancer cells is doing something qualitatively different from a simple cytostatic agent.

The Honest Complication — What Happened to Healthy Cells

This is where the study delivers a finding that demands careful consideration rather than celebration.

The noncancerous prostate epithelial cell lines — PWR-1E and RWPE-1 — were not spared by CBD. Under serum deprivation conditions, these healthy cells were slightly more sensitive to CBD than the cancer cell lines, with IC50 values of 0.9 micromolar and 1.1 micromolar respectively. And when PWR-1E cells were examined under fluorescence microscopy, the mechanism of that reduced viability was apoptosis — programmed cell death — rather than the proliferation inhibition seen in cancer cells.

This is the kind of finding that separates rigorous science from promotional science. The researchers did not bury this result or explain it away. They presented it, contextualised it honestly, and identified it as a direction for further investigation. The practical conclusion is not that CBD is unsafe — it is that understanding the difference in how CBD affects cancer versus normal prostate cells requires more work, including in vivo studies and more physiologically realistic cell models.

Connecting This Week to the Broader Series

Three weeks ago we mapped eight cancer types and five mechanisms across the broad cannabis-cancer literature. Prostate cancer was one of them, with the finding that cannabis extract and CBD increased caspase activity, upregulated TP53 and Bax, and reduced tumour size in mouse experiments when combined with cisplatin. This study goes deeper into the prostate cancer story — it adds mechanistic detail at the level of individual cell cycle proteins, identifies a receptor-independent mechanism of action, and provides the first direct evidence that CBD reduces CDK1 expression in cancer.

Last week's ovarian cancer study introduced the PTEN/PI3K/AKT/mTOR axis as a central mechanism of CBD:THC combination action, and showed that AKT phosphorylation was one of the primary targets. This week's study confirms AKT phosphorylation reduction in a different cancer by CBD alone — strengthening the case that this is not a cell-line-specific quirk but a genuine feature of how CBD interacts with cancer cell signalling.

The E-cadherin finding also connects to the broader anti-metastatic picture. Across this series, we have documented cannabinoids reducing invasion through TIMP-1 upregulation in lung cancer, through CSF-1 depletion in melanoma, and now through E-cadherin restoration in prostate cancer. Each mechanism is distinct, which suggests cannabinoids are not hitting a single anti-metastatic target but are capable of disrupting the metastatic programme through multiple independent routes depending on the cancer type.

What Comes Next

The authors are explicit about what this study does and does not establish. It is an in vitro study — 2D cell culture models that do not capture the complexity of a living tumour. The next steps they identify include testing in 3D cell culture models, which better reflect the architecture of real tumours, and in animal models, which would reveal whether the effects observed in cell culture translate to a living organism with intact vasculature, immune function, and drug pharmacokinetics.

The receptor question also remains open. Knowing that CBD's effects are not mediated by CB1, CB2, TRPV1, or GPR55 is a useful piece of negative information, but it does not yet tell us which target is responsible. Identifying that target would clarify the mechanism, inform dosing strategies, and potentially enable the design of CBD analogues with enhanced specificity or potency against prostate cancer cells.

For a cancer that kills hundreds of thousands of men annually, and for which metastatic and castration-resistant forms remain essentially without curative options, the data presented in this study represents a credible early-stage signal worth following. The cell cycle proteins are real. The AKT effect is real. The E-cadherin shift is real. The path from cell culture to clinical application is long and uncertain, but this study makes the journey worth attempting.